News & Events

Microbiotica Statement About Chairman Thomas Lynch

Microbiotica Statement About Chairman Thomas Lynch

Cambridge, UK, 14 May 2020 - It was with great sadness that the Board of Microbiotica learned of the death of its Chairman, Thomas Lynch, who passed away on 1st April 2020. Thomas had been Chairman of Microbiotica since September 2019 and brought a wealth of experience and guidance to the Board. Thomas had a highly successful and lengthy career with major impacts on many enterprises, spanning the biotech/pharma, hospital and charity sectors, both in his native Ireland and in multiple countries. He will be missed by all at Microbiotica, and by all who knew him. The Board's sincere condolences go to his family.

Sam Williams, Investor Director for IP Group, will assume the role of Acting Chairman with immediate effect. Sam was Chairman of the Microbiotica Board prior to Thomas taking up the role.

Notes To Editors

About Microbiotica

Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of best-in-class differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform.

Consisting of the world’s leading microbiome Reference Genome Database, Culture Collection, mass culturing technology (Personalised Bacterial Bank) and proprietary AI tools, Microbiotica’s platform enables unrivalled strain-level microbiome analysis linked to patient phenotypes. The Company’s current therapeutic areas of focus are immuno-oncology and IBD, and it has established major clinical and academic partnerships, including a $534m collaboration with Genentech.

Spun out of the Sanger Institute in 2016 by Dr Mike Romanos, Dr Trevor Lawley and Professor Gordon Dougan FRS, the Company is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute. Microbiotica’s investor syndicate includes Cambridge Innovation Capital, IP Group plc and Seventure Partners.

For more information, please visit, LinkedIn and Twitter.


Issued for and on behalf of Microbiotica by Instinctif Partners.
For more information please contact:

back to news